Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MAXCYTE, INC. (MXCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.6% stake in MAXCYTE, INC. |
| 01/10/2023 |
SC 13G/A
| Casdin Capital, LLC reports a 9% stake in MaxCyte, Inc. |
| 12/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD, 1 December, 2022: MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announces the appointment of Patrick J. Balthrop, Sr. to the company’ s Board of Directors as non-executive director with immediate effect. Mr. Balthrop is also appointed as non-executive member of the Nominating and Corporate Governance Committee. Mr. Balthrop has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools, and medical devices. He was CEO, Presiden..." |
|
| 11/29/2022 |
144
| Form 144 - Report of proposed sale of securities: |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/30/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/09/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/12/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...|
Docs:
|
"MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD, April 12, 2022 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. Ron Holtz, current Senior Vice President and Chief Accounting Officer, has been named Interim Chief Financial Officer effective upon Ms. Murphy’ s departure. Following her departure, Ms. Murphy intends to provide consulting services to ..." |
|
| 03/22/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/22/2022 |
8-K
| Quarterly results |
| 02/15/2022 |
SC 13G
| BAMCO INC reports a 5.1% stake in MAXCYTE, INC. |
| 02/11/2022 |
SC 13G
| Sofinnova Crossover I reports a 5.1% stake in MaxCyte, Inc. |
|
|
|